Heart failure & cardiomyopathiesCross-sectional study
First clinical experience with the Transthyretin Amyloidosis-Quality of Life questionnaire (ATTR-QoL): associations with clinical characteristics and established patient-reported outcomes
- cross-sectional study
- consecutive ATTR patients
- Columbia University
Authors' conclusion
ATTR-QOL, as a disease-specific PRO, effectively captures the multidimensional impact of ATTR and is associated with clinical parameters and functionality in patients with ATTR.
Study context
- Population
- Consecutive ATTR patients at Columbia University between 3/2024 and 1/2025 who completed the ATTR-QOLpatients included · cardiomyopathy 137 · mixed 48 · neuropathy 9
- Participants
- 194 patients
- Exposure
- ATTR-QOL against clinical parameters, functionality testing (6-minute walk test, Short Physical Performance Battery Test) and established patient-reported outcome (PROs) (Kansas City Cardiomyopathy Questionnaire (KCCQ), SF36v2, COMPASS-31)
Main finding
As reported in the abstract
Convergent validity of ATTR-QOL
- ATTR-QOL exhibited good convergent validity with clinical parameters, functionality testing, and established quality of life (QOL) tools
Observational data: associations, not effects.
Further findings
Known-groups discriminant validity of ATTR-QOL
- ATTR-QOL demonstrated strong known-groups discriminant validity, differentiating between various clinical and functional groups and established PRO categories
Disease stage (National Amyloidosis Centre (NAC))
- NAC Stage 1
- 70%
- NAC Stage 2
- 22%
- NAC Stage 3
- 8%
- All on disease-modifying treatment
Original publication
First clinical experience with the Transthyretin Amyloidosis-Quality of Life questionnaire (ATTR-QoL): associations with clinical characteristics and established patient-reported outcomes. Eur Heart J Qual Care Clin Outcomes. Published 12 February 2026. doi:10.1093/ehjqcco/qcag015
Summarised from the published abstract; every number is checked against it